rAd26-S

BIOLOGICAL3 trials

Sponsors

R-Pharm

Conditions

COVID-19

Phase 1

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

CompletedNCT04684446

R-PharmCOVID-19

Start: 2021-09-15End: 2022-03-29Updated: 2022-06-03

Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)

CompletedNCT04760730

R-PharmCOVID-19

Start: 2021-07-13End: 2022-07-26Updated: 2022-10-26

Phase 2

Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention

CompletedNCT04686773

R-PharmCOVID-19

Start: 2021-03-05End: 2022-03-18Updated: 2022-06-03